Financial Performance Summary

Q2 FY27 Performance (YoY Comparison):

  • Consolidated Revenue: ₹280 crores (43% growth from ₹196 crores in Q2FY26)
  • Consolidated EBITDA*: ₹94 crores (88% growth from ₹50 crores in Q2FY26)
  • Consolidated PAT: ₹52 crores (169% growth from ₹19 crores in Q2FY26)
  • *Excludes one-time IPO expense of approximately ₹3 crores

H1 FY27 Performance (YoY Comparison):

  • Consolidated Revenue: ₹498 crores (25% growth from ₹399 crores in H1FY26)
  • Consolidated EBITDA*: ₹140 crores (29% growth from ₹108 crores in H1FY26)
  • Consolidated PAT: ₹66 crores (34% growth from ₹49 crores in H1FY26)

API Business Performance:

  • Q2FY27 Operating Revenue: ₹227 crores (16% YoY growth from ₹196 crores)
  • H1FY27 Operating Revenue: ₹442 crores (11% YoY growth from ₹399 crores)
  • Q2FY27 EBITDA: ₹71 crores (21% YoY growth from ₹59 crores)
  • H1FY27 EBITDA: ₹137 crores (15% YoY growth from ₹119 crores)
  • API Gross margins maintained above 60%
  • API EBITDA margins steady at approximately 30%

Complex Injectables Business:

  • Recognized milestone-based revenue of ₹53 crores in Q2FY27 from licensing agreement for two DCV products in US
  • H1 expenses for new businesses: Operational expenses of ₹57 crores (including ANDA filing fees) and depreciation of ₹24 crores

Operational Highlights

API Products:

  • Sales growth of 11% in H1 FY27
  • Successfully completed 4 major regulatory audits:
  • EUGMP audits at Rau and Pithampur plants in March 2026 - Approval certification received for both plants
  • USFDA audits in H1 FY27 at Rau & Pithampur plants - EIR received for both plants

Complex Injectables:

  • Licensing agreement signed for distribution of two DCV products in US
  • First molecule ANDA for DCV filed and accepted by USFDA successfully (first generic filing for DCV product in US market)
  • Second ANDA filing scheduled for Q4 FY27 with Pre-submission Facility Correspondence (PFC) submitted qualifying for expedited Priority Review

Biotech - CDMO Services:

  • Industrial Biotech:
  • 10-year take-or-pay agreement with US-based Alternate Protein player in place with project capex on track
  • 10-year take-or-pay term sheet with Europe-based Alternate Protein player in advanced stages of agreement signing with initial manufacturing to commence in Q4
  • Pharmaceutical - Insulin Drug Substance:
  • 5-year take-or-pay agreement in place with capex on track
  • Regulatory approval filing scheduled for Q4 FY27 / Q1 FY28

Capital Expenditure Update

  • Total gross capex estimated at approximately ₹1,672 crores by end of FY27
  • 61% of total gross capex (₹1,000 crores) invested in new revenue generating businesses
  • Revenue for majority of new capacities already contracted with commencement expected in next 6-12 months
  • H1FY27 gross capex invested: approximately ₹113 crores

Financial Position

  • Net Debt as on September 30, 2026: approximately ₹314 crores

Management Commentary

Mr. Anil Satwani, Chairman & Managing Director, stated that Q2 FY27 performance reflects strong business momentum with continued progress in core business and scaling of emerging growth engines. API business delivered steady 11% YoY growth in H1FY27 with healthy volume growth and favorable product mix. Commercial supplies for DCV products expected to commence next year. The company remains confident in growth outlook with injectables and CDMO businesses having potential to scale meaningfully over coming years.

Website Information

The financial results are available on the company website at https://investor.symbiotec.com/financials?tab=press